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 Solid organ transplantation coupled with a hematopoietic stem cell transplant 
from the organ donor allows for the recipient to cease immunosuppressive therapy after 
transplant via a chimeric immune system.  This beneficial effect of stem cell transplants 
is negatively affected by graft versus host disease (GVHD).  Better understanding of the 
donor and recipient’s immune system is vital to mitigating graft versus host disease and 
induction of donor chimerism without GVHD.  In this study, flow cytometry was used to 
characterize immune cells of the recipients’ before and up to eighteen months post 
transplantation.  The recipients were categorized into their respective chimeric groups.  
Fully durable chimeric subjects did not reconstitute naïve T cells to pre-transplant levels 
by eighteen months post-transplant whereas the transiently chimeric subjects 
reconstituted.  The goal was to find an immune cell biomarker for chimerism but due to 
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 Hematopoietic stem cell (HSC) transplantation in conjunction with a solid organ 
transplant is in its infancy but has shown very promising results [1].  One of the major 
concerns with HSC transplantation is graft versus host disease (GVHD) [2].  The donor 
cells will mount an immune response against the recipient, ultimately causing rejection of 
transplanted cells and organ.  Without HSC transplantation along with the solid organ 
transplant, the recipient is confined to a regiment of constant immunosuppressive drug 
therapy for the remainder of his/her life [3].  This poses negative side effects which 
include a reduced immune system and an increased risk of developing cancer and 
opportunistic infections [4].  However, with the HSC transplant, the recipient will still 
take immunosuppressive drugs for a short period of time and then cease treatment to 
allow time for the donor and recipient cells to form a chimeric immune system where 
both the recipient and donor cells are active and cooperative [5]. 
 Due to the toxicity of immunosuppressive therapies [6] [7], Dr. Ildstad and her 
group have pioneered a HSC transplant model, known as facilitating cell treatment 
(FCRx), which relies on the enrichment of CD8+/TCR- facilitating cells (FC) and HSCs 
by depleting GVHD-producing cells.  FCRx transplants from the donor of a living kidney 
have been shown to induce a chimeric immune system in recipients of combined kidney 
and FCRx transplants [8].  This model is currently in FDA clinical trial for humans and 
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its aim is to eliminate the long term usage of immunosuppressive therapies via chimerism 
[9] [10]. 
The conditioning for FCRx transplant comprises a number of chemical and 
radiation treatments.  Fludarabine is administered at days -4, -3, and -2 pre-transplant and 
interferes with DNA synthesis.  Cyclophosphamide (Cy) is given at day -3 and interferes 
with DNA replication.  Tacrolimus, which inhibits IL-2 production to inhibit the 
development and proliferation of T cells, and mycophenolate mofetil (MMF), which 
inhibits an enzyme needed for the growth of T and B cells, treatment starts at day -2 and 
is continued after transplantation.  An irradiation of 200 cGy total body irradiation (TBI) 
is performed at day -1.  On day 0, the kidney transplant is performed and the FCRx 
infusion is performed day +1.  Another treatment of Cy is administered at day +3.  At this 
point, the recipient’s immune system is reduced to very low levels of white blood cells 
(WBC).  Engraftment of donor cells and recovery of recipient cells is monitored and 
determined at certain time points post-transplant.  MMF is ceased at 6 months post-
transplant and tacrolimus at 12 months if a stable level of donor chimerism is determined 
[5].  A timeline of conditioning and events is presented in Figure 1. 
Massachusetts General Hospital (MGH) and Stanford are also working with a 
combined HSC and organ transplant model to achieve chimerism.  The MGH group 
concentrates on tolerance via achieving transiently mixed chimerism [11].  Stanford 
achieved a persistent mixed chimerism in combined transplant subjects that were human 
leukocyte antigen (HLA) matched donor and recipient but zero chimerism in HLA 
mismatched transplants [11].  The Northwestern group with the Institute of Cellular 
Therapeutics (ICT, University of Louisville) has thirty five subjects that received a 
3 
 
combined transplant and eighteen recipients that have successfully ceased all 
immunosuppressive therapies with full donor chimerism induction. 
 While the FCRx transplant model aids in inducing chimerism, not all subjects in 
the clinical trial fully develop durable chimerism.  Within the scope of my work, there 
were eight human subjects that obtained a fully durable chimerism (100% donor DNA in 
recipient CD3+ cells and whole blood), four that showed chimerism after transplantation 
and infusion but regressed between months one and three post transplantation and are 
termed transient, and one that never developed chimerism.  The knowledge gap that we 
addressed in this work is to determine if there are differences in certain immune cell 
populations between the fully durable and transiently chimeric groups post 
transplantation. 
Hypothesis: 
 Characterizing the immune cell populations of the recipient pre- and post-
transplantation is important to determine if varying levels of chimerism result in 
differences in the repopulation of immune cell subsets.  Regulatory T cells are involved 
in downregulating the immune system [12] and may be involved in aiding induction of 
chimerism long term.  The hypothesis was that we would find a divergence of at least one 
immune cell type between the two chimeric groups, fully durable and transiently 











METHODS AND MATERIALS 
 
Institutional Review Boards (IRB) at Northwestern University and the University 
of Louisville approved all protocols in addition to the FDA (IDE 13947 & 7392).  Donors 
and recipients provided informed consent for admission into the clinical trial program. 
Obtaining Samples: 
Whole blood human samples from both recipient and donor were obtained in a 
Beckson Dickson (BD) acid citrate dextrose vacutainer tube from Northwestern 
Memorial Hospital in Chicago, Illinois and delivered the next day to the University of 
Louisville, Louisville, Kentucky.  A complete blood count (CBC) was performed in 
duplicate and the average WBC was recorded at receipt of each sample on a Horiba 
Micros 60 cell counter. 
Sample Staining: 
Third party, healthy human donor whole blood was used for unstained and single 
color compensation controls to properly set the parameters on the flow cytometer and 
followed staining steps for tubes that did not have intracellular markers added. 
Samples were stained in Fisher flow tubes using 20µl of BD extracellular 
antibodies that were previously titrated on third party, healthy human donor whole blood 
for optimal staining.  Upon antibody staining, the cells were incubated at 4°C for 30 
minutes.  After incubation, the cells were gently ratcheted to break up any pellets that 
may have occurred during incubation and washed with 2ml of an in-house flow stain 
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buffer and the tubes were placed in a centrifuge set for 200g, 4°C, for 5 minutes.  
The flow stain buffer was made by adding 1.8g sodium bicarbonate from Sigma-Aldrich 
(catalog #S8875), 5.0g Bovine Serum Albumin from Sigma-Aldrich (catalog #A7030), 
5.0g sodium azide from Sigma-Aldrich (catalog #S2002), to a Hank’s Balanced Salt 
Solution from Lonza BioWhittaker (catalog #10547F), which was diluted to a 1X 
concentration with endotoxin free water obtained from a Millipore water purification 
system.  After centrifugation, the supernatant was decanted from the tubes, ratcheted to 
break up pellets, and washed with 1ml Fixation/Permeabilization Buffer created using 
eBioscience Fixation/Permeabilization Concentrate (catalog #00-5123-43) and 
Fixation/Permeabilization Diluent (catalog #00-5223-56) and vortexed.  This step was 
used for all samples since some underwent intracellular staining and consistency in 
preparation was desired.  The cells were incubated at 4°C in the dark for 1 hour if no 
intracellular markers were to be used or 15 hours under the same conditions if 
intracellular markers were to be added.  Upon completion of the incubation, 2ml of the 
in-house flow stain buffer was added and the cells were placed in a centrifuge set for 
200g, 4°C, for 5 minutes.  The supernatant was decanted and the tubes ratcheted before 
adding 2ml of Permeabilization Buffer from eBioscience (catalog #00-833-56) diluted to 
a 1x concentrate with Dulbecco's phosphate-buffered saline (DPBS) from BioWhittaker 
(catalog #17-512Q) and placed in a centrifuge set for 200g, 4°C, for 5 minutes before 
decanting the supernatant and the tubes ratcheted. 
Subject sample cells that required intracellular staining had 20µl of 10% goat 
serum from Sigma-Aldrich (catalog #G9023) added as a blocking agent and incubated at 
4°C in the dark for 30 minutes, then BD intracellular antibodies were added to the tubes 
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and the tubes were incubated again at 4°C in the dark for 30 minutes.  After incubation, 
2ml of diluted Permeabilization Buffer was added to the tubes with intracellular markers.  
The supernatant was decanted and the tubes ratcheted. 
The sets of tubes with and without intracellular markers were washed with 2ml of 
the in-house flow stain buffer and the cells were placed in a centrifuge set for 200g, 4°C, 
for 5 minutes.  The supernatant was decanted and the tubes ratcheted.  400µl of the in-
house flow stain buffer was added to the tubes and they were vortexed before flow 
cytometry acquisition. 
Flow Cytometry: 
The prepared controls and subject samples were acquired on a BD LSRII flow 
cytometer with a threshold set to eliminate any remaining red blood cells still present in 
any of the tubes.  The flow cytometer rate was set at medium to reduce the possibility of 
doublets occurring in the flow cell.  Forward Scatter (FSC) and Side Scatter (SSC) were 
adjusted on the unstained subject sample tube after compensation was set.  Each tube was 
acquired until 100,000 total events were recorded. 
Samples were analyzed using BD FACSDiva software.  The number of CD4+ 
regulatory T cells was recorded along with the total number of events.  The absolute cell 
number was calculated by multiplying the WBC number by the percent of the cell 
population of interest. 
Statistical Analysis: 
Subjects were grouped into their respective chimerism groups and the average 
among the chimeric group was determined for each time point.  Standard error of the 
mean was calculated and used for generating error bars in the graphs.  A two-tailed 
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Student’s t-test with unequal variance was performed to compare the fully durable to the 
transiently chimeric groups at each time point.  This was because the two chimeric 
groups are unequal in the number of subjects in their respective groups.  A p-value of 





 Clinical subjects were sorted into sets of chimeric groups.  Fully durable 
chimerism includes subjects that developed a homeostatic chimeric immune system 
between the recipient and the donor.  These subjects were weaned off of 
immunosuppressive therapies by twelve months post kidney transplantation.  Transiently 
chimeric subjects started showing decreased levels of chimerism between months one 
and three post combined kidney/FCRx transplant, but showed zero percent chimerism in 
their whole blood by twelve months post transplantation.  These subjects have to continue 
immunosuppressive therapies.  One subject never obtained a level of chimerism above 
zero percent.  In total, there are eight subjects that are fully chimeric, four that are 
transient, and one that never became chimeric and the chimeric groups are listed in Table 
1. 
 Lineage reconstitution of FCRx recipients was monitored and assessed.  Due to 
the conditioning, the absolute cell number of CD3+ cells showed a decrease post-
transplantation.  B cells and NK cells recovered faster than T cells and, by six months 
post-transplant, were larger in number than pre-transplant levels in both chimeric groups 
and are shown in Figures 2 and 3 [5].  Interestingly, the transiently chimeric subjects’ NK 
cells exceeded the pre-transplant absolute cell number by eighteen months post-
transplantation.  Since the transiently chimeric subjects are no longer tolerant, their NK 
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cells could be mounting a response to the foreign graft including donor cells [13]. 
 CD4+ and CD8+ subpopulations of CD3+ T cells were also characterized.  Effector 
memory cells (Tem) were defined as CD45RA-/CD45RO+/ CD62Llow, central memory 
cells (Tcm) as CD45RA-/CD45RO+/ CD62Lhigh, effector cells (Teff) as 
CD45RA+/CD45RO-/CD62L-, and naïve T cells as CD45RA+/CD45RO-/CD62L+ and the 
gating strategy is shown in Figure 4.  Within twelve months post-transplantation, the 
CD4+ and CD8+ Tem, Tcm, and Teff subpopulations reconstituted to a level not 
significantly different than pre-transplant cell numbers for both chimeric groups as shown 
in Figures 5 and 6.  Naïve CD4+ subpopulations, however, did not return to pre-transplant 
levels and is reflected in both fully durable and transiently chimeric groups [5].  The 
naïve CD8+ cells did not return to pre-transplant levels for the fully durable group but did 
return to a similar state for the transiently chimeric subjects by nine months post-
transplant. 
 Regulatory T cells were defined as CD4+/CD25+/FoxP3+ and our gating strategy 
is listed in Figure 7.  Comparing the fully durable to the transiently chimeric groups, I 
found there to be no significant difference pre combined kidney/FCRx transplant, which 
was to be expected.  Three months post-transplant, data showed that both chimeric 
groups had drastically reduced levels of regulatory T cells due to the subjects’ irradiation 
and immunosuppressive therapies.  Considering Figure 8, once MMF was discontinued, a 
divergence of the regulatory T cells was observed between fully durable and transiently 
chimeric subjects, which became more prominent at twelve months, when tacrolimus was 
discontinued, and even more at eighteen months post-transplantation, though there was 
no significant difference.  The transiently chimeric subjects’ regulatory T cells never 
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Chimeric Subject Groups of Living Kidney and FCRx Transplant 
Subject Chimeric Group 
Month 12 Percent Whole Blood Donor 
Chimerism 
NW1 Transient 0% 
NW2 Off Study Off Study 
NW3 Fully Durable 100% 
NW4 Transient 0% 
NW5 Fully Durable 100% 
NW6 Fully Durable 100% 
NW7 Fully Durable 100% 
NW8 Fully Durable 100% 
NW9 0% Chimeric 0% 
NW10 Fully Durable 100% 
NW11 Transient 0% 
NW12 Transient 10% 
NW13 Off Study Off Study 
NW14 Fully Durable 100% 






Figure 2.  Lineage populations for the fully durable chimeric group.  CD3+, CD19+ B 
cells, CD56+ NK cells, and CD14+ monocytes absolute cell numbers are shown.  This 






Figure 3.  Lineage populations for the transiently chimeric group.  CD3+, CD19+ B cells, 
CD56+ NK cells, and CD14+ monocytes absolute cell numbers are shown.  This data was 






Figure 4.  The gating strategy for T cell subpopulations on the BD LSRII is shown.  
lymphocytes were selected (P1 gate in top left dot plot), followed by CD4+ and CD8+ 
(bottom left dot plot) followed by effector memory cells (Tem) as CD45RA-/CD45RO+/ 
CD62Llow, central memory cells (Tcm) as CD45RA-/CD45RO+/ CD62Lhigh, effector cells 






Figure 5.  CD4+ and CD8+ subpopulations for the fully durable chimeric group.  Tem, 
Tcm, naïve, and Teff absolute cell numbers are shown.  Naïve CD4+ and naïve CD8+ cells 






Figure 6.  CD4+ and CD8+ subpopulations for the transiently chimeric group.  Tem, Tcm, 








Figure 7.  The gating strategy for regulatory T cells on the BD LSRII is shown.  
Lymphocytes were selected (P1 gate in the top left dot plot), followed by CD4+ cells (top 
right dot plot), then CD25+ cells (bottom left dot plot), and finally CD25+/FoxP3+ cells 
(CD4+/CD25+/FoxP3+ regulatory T cells). 




Figure 8.  CD4+ regulatory T cells shown for each time point as an average within the 
fully durable and transiently chimeric groups.  Though the transient subjects had higher 
levels of regulatory T cells, than the fully durable group, pre-transplant and lower levels 

































 Studies on chimeric immune systems have not been able to show a biomarker that 
accurately predicts successful, durable chimerism after the cessation of 
immunosuppressive therapy.  Consequentially, 80% of subjects that are weaned off of 
immunosuppression undergo rejection and must be placed on immunosuppressive 
therapy again [14] [15].  This impact is of vital consequence because rejection has 
previously been linked to the survival of the sold organ transplant [16]. 
 The scope of this thesis’ work was to characterize the immune cells in these 
subjects and potentially find a trend of divergence between the fully durable and the 
transiently chimeric subjects.  While most cell types showed no significant difference 
between the two groups, the post-transplant CD8+ naïve T cells and CD4+ regulatory T 
cells, that were measured, alluded to a pattern of divergence from pre-transplant levels.  
Despondently, because the transiently chimeric group had only four subjects, the range of 
data for the aforementioned cell types is extensive and no significant difference between 
the chimeric groups was able to be ascertained. 
Future Experiments: 
 Due to the transiently chimeric group only having four subjects, it would be of 
scientific benefit to have a greater number of subjects that lost chimerism after transplant 
and before immunosuppressive therapy was ceased.  While this is not ideal for subjects 
and the ultimate goal of the combined kidney + FCRx transplant model is to induce 
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chimerism, a greater understanding of the aberration of the CD8+ naïve T cells and the 
CD4+ regulatory T cells of transiently chimeric subjects versus fully durable subjects may 
lead to the discovery of a predictive biomarker for chimerism. 
 There are other immune biomarkers that may possibly predict chimerism in 
subjects that received a combined transplantation.  Dysregulation of miRNA levels in 
urine analysis has been observed in diseased conditions of kidney transplants [17] [18].  
Elevated levels of the exosome neutrophil gelatinase-associated lipocalin (NGAL), have 
been shown to be early predictors of delayed transplant function [19].  Early detection of 
transplant rejection can be assessed by detecting low levels of PARP1 in the recipient’s 
serum [20].  These potential biomarkers are minimally invasive, may detect transplant 
rejection at an early onset, and should be explored further. 
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SUMMARY AND CONCLUSION 
 
 The characterization of select immune cells in subjects enrolled in the combined 
kidney + FCRx study has shown that naïve CD4+, naïve CD8+, and regulatory T cells 
repopulate at different rates between fully durable and transiently chimeric subjects post-
transplantation.  While the limited number of subjects in the transiently chimeric group 
presented a shortcoming in the form of a wide range within those cell types, this work 
warrants further investigation to determine if naïve CD4+, naïve CD8+ T cells, and or 
CD4+ regulatory T cells may potentially be a predictive biomarker for successful 
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